Prodromal Parkinson's Disease: The Decade Past, the Decade to Come
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The past decade has seen a dramatic expansion of the field of prodromal PD. Ten years ago, there were only six known prodromal markers of disease, none of which had more than two studies documenting diagnostic value. We now have at least 16 markers, with as many as 10 prospective studies for a single marker. This review summarizes the major advances over the last decade and speculates about the advances we will see in the decade to come. The most notable advances over the last decade came through the study of high‐risk cohorts (REM sleep behavior disorder and later genetic and autonomic cohorts), the generation of more representative population‐based cohorts for studying prodromal PD, major advances in neuroimaging of early disease stages, the emerging likelihood that tissue biopsy will be able to diagnose prodromal PD, and the coalescence of prodromal markers into discrete criteria. As the next decade dawns, we await increasing precision of sensitivity and specificity estimates of known markers, the discovery of new biomarkers of prodromal disease, improvements in diagnosis using combined methods/criteria (with increasing recognition of prodromal PD as one stage of the full PD spectrum), and ultimately the development of neuroprotective therapy that can be provided at the earliest stages of disease. © 2019 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“The Braak staging model had been published 5 years before.(1) This”
MethodDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationThe prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 1×
“However, LRRK-2 and GBA mutations are relatively common in PD, with sufficiently high penetrance to warrant collection.(64) These mutation carriers are also an important potential group in which to test neuroprotective interventions (targeted therapy like LRRK-2 inhibitors, enzyme replacement or substrate-reduction th…”
BackgroundSelf-citationFrequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.009 · Cited by 814
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674
Alpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients
Iranzo, A., Fernández-Arcos, A., Tolosa, E., Serradell, M., Molinuevo, J. L., Valldeoriola, F., Gelpi, E., Vilaseca, I., Sánchez-Valle, R., Lladó, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089741 · Cited by 548
Boeve, B. F., Silber, M. H., Ferman, T. J., Lin, S. C., Benarroch, E. E., Schmeichel, A. M., Ahlskog, J. E., Caselli, R. J., Jacobson, S., Sabbagh, M., et al. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.015 · Cited by 393
Knudsen, K., Fedorova, T. D., Hansen, A. K., Sommerauer, M., Otto, M., Svendsen, K. B., Nahimi, A., Stokholm, M. G., Pavese, N., Beier, C. P., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30162-5 · Cited by 309 · cited 3×
“Similarly, loss of neuromelanin signal in locus ceruleus and SN were documented in early PD(85) and in RBD.(98) Prospective proof of predictive efficacy is still pending for neuromelanin studies.”
BackgroundInfluentialLipsmeier, F., Taylor, K. I., Kilchenmann, T., Wolf, D., Scotland, A., Schjodt‐Eriksen, J., Cheng, W., Fernandez‐Garcia, I., Siebourg‐Polster, J., Jin, L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27376 · Cited by 266
Self-citationNew methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review
Sánchez‐Ferro, Á., Elshehabi, M., Godinho, C., Salkovic, D., Hobert, M. A., Domingos, J., van Uem, J. M., Ferreira, J. J., & Maetzler, W. (2016) · Movement Disorders · doi:10.1002/mds.26723 · Cited by 145
A prospective study of bowel movement frequency and risk of Parkinson's disease
Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr119 · Cited by 115
Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study
Ferini-Strambi, L., Oertel, W., Dauvilliers, Y., Postuma, R. B., Marelli, S., Iranzo, A., Arnulf, I., Birgit, H., Manni, R., Miyamoto, T., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7317-8 · Cited by 112
Self-citation
Cited by
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic
Kunz, D., Stotz, S., & Bes, F. (2021) · Journal of Pineal Research · doi:10.1111/jpi.12759 · Cited by 42
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans
Scott, G. D., Lim, M. M., Drake, M. G., Woltjer, R., & Quinn, J. F. (2021) · Movement Disorders · doi:10.1002/mds.28636 · Cited by 42
Drobny, A., Ngo, P. A., Neurath, M. F., Zunke, F., & López-Posadas, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655123 · Cited by 24
Cortes-Flores, H., Torrandell-Haro, G., & Brinton, R. D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1358568 · Cited by 12
Metadata
- Authors
- Postuma, R. B., & Berg, D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2019-03-28
- Volume
- 34
- Issue
- 5
- Pages
- 665-675
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2934709382
- Cited by
- 223
- References
- 18
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.